Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics

Research output: Contribution to journalReview article

Authors

External Institution(s)

  • LSU Health Sciences Center - Shreveport

Details

Original languageEnglish (US)
Pages (from-to)706-718
Number of pages13
JournalAmerican Journal of Pathology
Volume189
Issue number4
StatusPublished - Apr 2019
Peer-reviewedYes

Abstract

Sickle cell disease (SCD) is one of the most common hereditary hemoglobinopathies worldwide, affecting almost 400,000 newborns globally each year. It is characterized by chronic hemolytic anemia and endothelial dysfunction, resulting in a constant state of disruption of the vascular system and leading to recurrent episodes of ischemia-reperfusion injury (I/RI) to multiple organ systems. I/RI is a fundamental vascular pathobiological paradigm and contributes to morbidity and mortality in a wide range of conditions, including myocardial infarction, stroke, acute kidney injury, and transplantation. I/RI is characterized by an initial restriction of blood supply to an organ, which can lead to ischemia, followed by the subsequent restoration of perfusion and concomitant reoxygenation. Recent advances in the pathophysiology of SCD have led to an understanding that many of the consequences of this disease can be explained by mechanisms associated with I/RI. The following review focuses on the evolving pathobiology of SCD, how various complications of SCD can be attributed to I/RI, and the role of timely therapeutic intervention(s) based on targeting mediators or pathways that influence I/R insult.